Vandetanib demonstrates antitumor activity, with a manageable safety profile, among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC), according to a study presented at the European Society for Medical Oncology (ESMO) 2016.1
RET rearrangements are identified as a rate oncogenic alteration in NSCLC; researchers therefore assessed the efficacy and tolerability of the kinase inhibitor, vandetanib, which possesses RET kinase inhibitory activity, among patients who present with this mutation.
For the multicenter, single-arm, phase 2 LURET study, researchers enrolled 19 patients with advanced RET-rearranged NSCLC who failed at least 1 prior line of chemotherapy. Half had received 3 or more prior chemotherapy regimens.
Among the 17 evaluable patients, 53% (95% CI, 31-74) achieved an overall response, including 9 partial responses. The disease control rate was 90%; median progression-free survival was 4.7 months (95% CI, 2.8-8.5).
Subgroup analyses demonstrated that the overall response rates were 83%, 20%, and 67% for patients with KIF5B-RET, 6 CCDC6-RET, and unknown rearrangements, respectively; median progression-free survival was 8.3, 2.9, and 4.7 months, respectively.
Researchers observed no significant differences in overall response rate or progression-free survival with respect to sex or smoking status.
The most frequently reported adverse events were hypertension, diarrhea, rash, dry skin, and corrected QT interval prolongation.
- Horiike A, Yoh K, Seto T, et al. LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC). Poster presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.